4,692 AbbVie Inc. $ABBV Shares Bought by Sax Wealth Advisors LLC

Key Points

• Sax Wealth Advisors increased its AbbVie position by 40.5% in the third quarter, adding 4,692 shares to hold 16,271 shares valued at approximately $4.26 million. Institutional investors collectively own 70.23% of the company.
• Analysts remain broadly positive, with AbbVie receiving a consensus “Moderate Buy” rating and an average price target of $277.18, though individual targets range from $247 to $300.
• AbbVie reported quarterly revenue of $16.99 billion and adjusted earnings of $3.65 per share, both ahead of expectations, while declaring a quarterly dividend of $1.73 per share, equivalent to a 2.5% yield.

Sax Wealth Advisors LLC lifted its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 40.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 16,271 shares of the company's stock after acquiring an additional 4,692 shares during the period. Sax Wealth Advisors LLC's holdings in AbbVie were worth $4,256,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. State Street Corp raised its holdings in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company's stock valued at $20,784,646,000 after buying an additional 1,379,232 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company's stock valued at $3,590,323,000 after buying an additional 106,091 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of AbbVie in the 2nd quarter worth approximately $2,905,952,000. Deutsche Bank AG grew its position in AbbVie by 13.0% in the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company's stock worth $2,710,905,000 after buying an additional 1,241,587 shares during the last quarter. Finally, Amundi raised its position in shares of AbbVie by 2.4% during the first quarter. Amundi now owns 10,698,095 shares of the company's stock worth $2,326,728,000 after purchasing an additional 247,689 shares during the period. Institutional investors and hedge funds own 70.23% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. BMO Capital Markets upped their price target on shares of AbbVie from $258.00 to $300.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. BNP Paribas Exane lifted their price target on AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a report on Tuesday, August 11th. Barclays boosted their price target on AbbVie from $275.00 to $300.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Argus increased their price objective on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Finally, Oppenheimer raised their price objective on shares of AbbVie from $244.00 to $258.00 and gave the company a "neutral" rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $277.18.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Stock Down 1.6%

Shares of NYSE:ABBV traded down $4.53 on Tuesday, reaching $276.59. The company had a trading volume of 1,887,364 shares, compared to its average volume of 6,390,898. The stock has a market capitalization of $488.67 billion, a P/E ratio of 78.17, a P/E/G ratio of 1.26 and a beta of 0.24. The stock has a 50-day moving average price of $259.79 and a 200 day moving average price of $237.39. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $283.43.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the firm posted $2.97 EPS. The firm's revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. AbbVie's dividend payout ratio is presently 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and set a $280 price target, indicating continued confidence in AbbVie’s outlook, although the target implies only modest near-term upside. TickerReport article
• Positive Sentiment: Skyrizi and Rinvoq are expected to be the primary drivers of third-quarter revenue growth, helping offset the continued decline of Humira. Long-term data presented at ACG 2026 also support the durability of these products. Yahoo Finance article
• Positive Sentiment: Investors remain focused on AbbVie’s pipeline expansion, including a recently completed acquisition and a new FDA approval that could create another billion-dollar growth opportunity. 247WallSt article
• Neutral Sentiment: AbbVie was highlighted in broader discussions of pharmaceutical merger activity, as large drugmakers pursue acquisitions to address upcoming patent cliffs. This supports sector interest but does not provide a company-specific catalyst by itself. ETF Trends article
• Negative Sentiment: Humira’s ongoing erosion and increasing competition in immunology remain key risks. In addition, AbbVie’s elevated valuation and the limited upside to RBC’s target may encourage investors to lock in gains after the stock’s recent rally. Motley Fool article

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.